JANX - Janux Therapeutics Inc
IEX Last Trade
47.03
2.390 5.082%
Share volume: 423,888
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$44.64
2.39
5.35%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-10 | 2023-03-10 | 2023-05-09 | 2023-08-08 | 2023-11-07 | 2024-03-08 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 385.365 M | 375.756 M | 364.010 M | 352.956 M | 341.500 M | 386.850 M | 380.407 M | 688.984 M | |
| Current Assets | 358.065 M | 344.330 M | 332.439 M | 321.399 M | 309.302 M | 355.195 M | 349.241 M | 658.666 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 3.769 M | 5.070 M | 5.423 M | 3.774 M | 6.013 M | 5.483 M | 5.213 M | 6.384 M | |
| Short Term Investments | 3.769 M | 5.070 M | 5.423 M | 3.774 M | 6.013 M | 5.483 M | 5.213 M | 6.384 M | |
| Total Receivables | 0.000 | 500.000 K | 0.000 | 750.000 K | 0.000 | 0.000 | 0.000 | 519.000 K | |
| Current Cash | 354.296 M | 338.760 M | 327.016 M | 316.875 M | 303.289 M | 349.712 M | 344.028 M | 651.763 M | |
| Total Non-current Assets | 27.300 M | 31.426 M | 31.571 M | 31.557 M | 32.198 M | 31.655 M | 31.166 M | 30.318 M | |
| Property Plant Equipment | 3.517 M | 6.514 M | 7.086 M | 7.203 M | 7.378 M | 7.317 M | 7.003 M | 6.517 M | |
| Other Assets | 22.967 M | 24.096 M | 23.669 M | 23.538 M | 24.004 M | 23.522 M | 23.347 M | 22.985 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 385.365 M | 375.756 M | 364.010 M | 352.956 M | 341.500 M | 386.850 M | 380.407 M | 688.984 M | |
| Total liabilities | 41.551 M | 44.243 M | 43.270 M | 41.692 M | 42.031 M | 37.902 M | 36.058 M | 33.221 M | |
| Total current liabilities | 12.994 M | 16.335 M | 16.507 M | 16.114 M | 17.904 M | 14.471 M | 13.033 M | 10.609 M | |
| Accounts Payable | 3.000 M | 2.866 M | 2.159 M | 2.051 M | 1.910 M | 2.505 M | 2.424 M | 2.254 M | |
| Other liabilities | 5.289 M | 3.816 M | 2.221 M | 1.394 M | 307.000 K | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 88.000 K | 0.000 | 763.000 K | 1.356 M | 1.408 M | 1.462 M | 1.517 M | 1.573 M | |
| Long term debt | 23.268 M | 24.092 M | 24.542 M | 24.184 M | 23.820 M | 23.431 M | 23.025 M | 22.612 M | |
| Other liabilities | 5.289 M | 3.816 M | 2.221 M | 1.394 M | 307.000 K | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 343.814 M | 331.513 M | 320.740 M | 311.264 M | 299.469 M | 348.948 M | 344.349 M | 655.763 M | |
| Common stock | 41.449 M | 41.527 M | 41.588 M | 41.764 M | 41.836 M | 45.709 M | 46.756 M | 49.050 M | |
| Retained earnings | -77.709 M | -94.405 M | -110.470 M | -127.929 M | -145.437 M | -157.005 M | -168.763 M | -183.523 M |